Three places where medicine gets chosen today — and pharma's old model can't reach. Peer-to-peer HCP engagement, AI answer monitoring, and NP/PA prescriber intelligence — a platform for each.
The prescriber is shutting the door on direct promotion. No-see rates rise, rep access shrinks — because the message is coming from the company that makes the product.
You reach them from outside the sales channel entirely: 650,000 verified clinicians, peer to peer. What's closed to the rep was never closed to the profession.
The first question about your brand is no longer asked to a rep. It's asked to a machine — and answered in a room no one from pharma is standing in. The decision forms inside the AI response, before you're in it.
We did this once for clinicians; now we do it for the models — giving AI the complete, sourced picture it needs to answer fairly, at the moment the decision starts.
NPs and PAs write more of the scripts every year, and pharma's call panel was built for physicians. The fastest-growing prescriber segment sits beyond the edge of the target — unsegmented, unmeasured. You can't call on who you can't see.
You bring the APP into focus: visibility, signaling, and measurement for the prescriber the panel forgot.
Medical innovation has never moved faster. Yet many important therapies remain misunderstood, underutilized, or overlooked.
Our mission is simple: to help healthcare professionals discover, evaluate, and understand the therapies changing patient lives.
Closing that distance is the whole of our business.
It is measured in time — days, weeks, sometimes years — and it is made of gaps. A prescriber who never hears. A patient who never learns the option exists. A prescription written but never filled. Every one of those gaps is a person waiting longer than they should for something that already exists to help them.
Our industry spends more every year to close that distance and closes less of it. The doors are shutting — not because clinicians stopped caring about medicine, but because they stopped wanting to hear about it from the company that makes it.
The prescribing decision has simply moved to places the manufacturer can’t reach — where the influence is real and the visibility is not.
And here is why we can go where our clients cannot: we are not the rep. We are not the brand. We are not the company that makes the medicine.
That distance is not a limitation we work around. It is the asset. Clinicians open doors to independent voices that they close to commercial ones. Patients trust what they did not have to be sold. Our independence is what earns the access — and what makes the access worth having.
Our work is the bridge. That is the path — and that is what we share.
With extensive experience in pharmaceutical commercialization, Jeff founded SharePath around a simple belief:
Great medicines deserve a trusted path into clinical conversation.
Today SharePath supports life sciences organizations through platforms that connect healthcare professionals, commercial teams, and emerging AI ecosystems.
The prescribing journey is evolving rapidly. Clinical conversations increasingly occur across professional networks, digital communities, and artificial intelligence platforms.
SharePath builds the platforms that reach into those conversations — independently, credibly, and on the clinician’s terms.
Start a Conversation